Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Net Income towards Common Stockholders (2016 - 2026)

Viking Therapeutics (VKTX) has disclosed Net Income towards Common Stockholders for 13 consecutive years, with -$158.3 million as the latest value for Q1 2026.

  • For Q1 2026, Net Income towards Common Stockholders fell 247.17% year-over-year to -$158.3 million; the TTM value through Mar 2026 reached -$472.4 million, down 268.29%, while the annual FY2025 figure was -$359.6 million, 227.0% down from the prior year.
  • Net Income towards Common Stockholders hit -$158.3 million in Q1 2026 for Viking Therapeutics, roughly flat from -$157.7 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$15.7 million in Q3 2022 and bottomed at -$158.3 million in Q1 2026.
  • Average Net Income towards Common Stockholders over 5 years is -$46.0 million, with a median of -$24.6 million recorded in 2023.
  • Year-over-year, Net Income towards Common Stockholders fell 10.44% in 2023 and then tumbled 345.56% in 2025.
  • Viking Therapeutics' Net Income towards Common Stockholders stood at -$19.6 million in 2022, then dropped by 25.72% to -$24.6 million in 2023, then tumbled by 44.0% to -$35.4 million in 2024, then plummeted by 345.56% to -$157.7 million in 2025, then fell by 0.39% to -$158.3 million in 2026.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods came in at -$158.3 million, -$157.7 million, and -$90.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.